Digestive Diseases and Sciences

, Volume 53, Issue 9, pp 2359–2365

Mechanisms of Action and Resistance of Somatostatin Analogues for the Treatment of Hepatocellular Carcinoma: A Message Not Well Taken

  • Dimitrios N. Samonakis
  • George Notas
  • Nikolaos Christodoulakis
  • Elias A. Kouroumalis
Review Paper

Abstract

Somatostatin (SST) acts as an inhibitory peptide of various secretory and proliferative processes. Apart from neuroendocrine tumors, where SST analogues have an established role, they have been tested in other tumors such as hepatocellular carcinoma (HCC) in the view of the fact that chemotherapy is not working. Several positive reports have been published. Approximately 40% of patients respond with improved survival and an impressive quality of life. A usual misunderstanding in trial designs is that, although SST is not a rescue drug, selection of patients is inappropriate, with mostly moribund patients being recruited. SST analogues do not seem to work in 60% of HCCs and this has been linked to the presence of SST receptors (SSTR) in the tumor, while several resistance mechanisms might be involved. Future management should engage more specific SST analogues targeted to a tumor with a known SSTR map. The use of somatostatin analogues as an adjunct therapy in combination with other treatment modalities should also be investigated.

Keywords

HCC Octreotide Lanreotide Somatostatin receptors Nonsurgical 

References

  1. 1.
    Thomas MB, Zhu AX (2005) Hepatocellular carcinoma: the need for progress. J Clin Oncol 23:2892–2899PubMedCrossRefGoogle Scholar
  2. 2.
    Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362:1907–1917PubMedCrossRefGoogle Scholar
  3. 3.
    Bosch FX, Ribes J, Diaz M, Cleries R (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127:S5–S16PubMedCrossRefGoogle Scholar
  4. 4.
    Fattovich G, Stroffolini T, Zagni I, Donato F (2004) Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127:S35–S50PubMedCrossRefGoogle Scholar
  5. 5.
    Branda M, Wands J (2006) Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma. Hepatology 43:891–902PubMedCrossRefGoogle Scholar
  6. 6.
    Kaposi-Novak P, Lee J, Gomez-Quiroz L, Coulouarn C, Factor V, Thorgeirsson S (2006) Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 116:1582–1595PubMedCrossRefGoogle Scholar
  7. 7.
    Thorgeirsson S, Grisham J (2002) Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31:339–46PubMedCrossRefGoogle Scholar
  8. 8.
    Llovet JM, Beaugrand M (2003) Hepatocellular carcinoma: present status and future prospects. J Hepatol 38(Suppl 1):S136–S149PubMedCrossRefGoogle Scholar
  9. 9.
    Varela M, Sala M, Llovet JM, Bruix J (2003) Review article: natural history and prognostic prediction of patients with hepatocellular carcinoma. Aliment Pharmacol Ther 17(Suppl 2):98–102PubMedCrossRefGoogle Scholar
  10. 10.
    Mela M, Mancuso A, Burroughs AK (2003) Review article: hepatocellular carcinoma: indications for liver transplantation. Aliment Pharmacol Ther 17 (Suppl 2):130–137PubMedCrossRefGoogle Scholar
  11. 11.
    Schwartz M (2004) Liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 10:S81–S85PubMedCrossRefGoogle Scholar
  12. 12.
    Song TJ, Ip EW, Fong Y (2004) Hepatocellular carcinoma: current surgical management. Gastroenterology 127:S248–S260PubMedCrossRefGoogle Scholar
  13. 13.
    Burroughs A, Hochhauser D, Meyer T (2004) Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol 5:409–418PubMedCrossRefGoogle Scholar
  14. 14.
    Schwartz JD, Beutler A (2004) Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-II: systemic and local non-embolization-based therapies in unresectable and advanced hepatocellular carcinoma. Anti-Cancer Drugs 15:439–52PubMedCrossRefGoogle Scholar
  15. 15.
    Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos ON (1998) Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 42:442–447PubMedGoogle Scholar
  16. 16.
    Samonakis DN, Moschandreas J, Arnaoutis T, Skordilis P, Leontidis C, Vafiades I, Kouroumalis E (2002) Treatment of hepatocellular carcinoma with long acting somatostatin analogues. Oncol Rep 9:903–907PubMedGoogle Scholar
  17. 17.
    Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisimopoulos A, Andriotis E, Panagiotakos D, Fotopoulou A, Chrysohoou C, Bazinis A, Daskalopoulou D, Paraskevas E (2007) Lond-acting Octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors. A randomized placebo controlled trial. World J Gastroenterol 13(23):3164–3170PubMedGoogle Scholar
  18. 18.
    Yuen MF, Poon RT, Lai CL, Fan ST, Lo CM, Wong KW, Wong WM, Wong BC (2002) A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 36:687–691PubMedCrossRefGoogle Scholar
  19. 19.
    Becker G, Allgaier HP, Olschewski M, Zahringer A, Blum HE (2007) Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology 45:9–15PubMedCrossRefGoogle Scholar
  20. 20.
    Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso MC, Sala M, Bru C, Rodes J, Bruix J (1999) Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 29:62–67PubMedCrossRefGoogle Scholar
  21. 21.
    Samonakis DN, Christodoulakis N, Kouroumalis EA (2006) Octreotide for unresectable hepatocellular carcinoma: beyond the first sight. J Clin Gastroenterol 40:86–87PubMedCrossRefGoogle Scholar
  22. 22.
    Raderer M, Hejna MH, Kurtaran A, Kornek GV, Valencak JB, Oberhuber G, Vorbeck F, Virgolini I, Scheithauer W (1999) Successful treatment of an advanced hepatocellular carcinoma with the long-acting somatostatin analog Lanreotide. Am J Gastroenterol 94:278–279PubMedCrossRefGoogle Scholar
  23. 23.
    Raderer M, Hejna MH, Muller C, Kornek GV, Kurtaran A, Virgolini I, Fiebieger W, Hamilton G, Scheithauer W (2000) Treatment of hepatocellular cancer with the long acting somatostatin analog Lanreotide in vitro and in vivo. Int J Oncol 16:1197–201PubMedGoogle Scholar
  24. 24.
    Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisimopoulos A, Andriotis E, Markidou S, Panagiotakos D, Chrysohoou C, Bazinis A, Paraskevas E (2002) The role of sandostatin LAR in treating patients with advanced hepatocellular cancer. Hepatogastroenterology 49:1245–1250PubMedGoogle Scholar
  25. 25.
    Siveke JT, Herberhold C, Folwaczny C (2003) Complete regression of advanced HCC with long acting octreotide. Gut 52:1531PubMedCrossRefGoogle Scholar
  26. 26.
    Gill ML, Atiq M, Sattar S, Khokhar N (2005) Treatment outcomes with long acting octreotide in inoperable hepatocellular carcinoma: a local experience and review of literature. J Pak Med Assoc 55:135–138PubMedGoogle Scholar
  27. 27.
    Reubi JC (2003) Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24:389–427PubMedCrossRefGoogle Scholar
  28. 28.
    Plentz RR, Tillmann HL, Kubicka S, Bleck JS, Gebel M, Manns MP, Rudolph KL (2005) Hepatocellular carcinoma and octreotide: treatment results in prospectively assigned patients with advanced tumor and cirrhosis stage. J Gastroenterol Hepatol 20:1422–1428PubMedCrossRefGoogle Scholar
  29. 29.
    Blaker M, Schmitz M, Gocht A, Burghardt S, Schulz M, Broring DC, Pace A, Greten H, De Weerth A (2004) Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas. J Hepatol 41:112–118PubMedCrossRefGoogle Scholar
  30. 30.
    Reubi JC, Zimmermann A, Jonas S, Waser B, Neuhaus P, Laderach U, Wiedenmann B (1999) Regulatory peptide receptors in human hepatocellular carcinomas. Gut 45:766–774PubMedCrossRefGoogle Scholar
  31. 31.
    Patel YC (1999) Somatostatin and its receptor family. Front Neuroendocrinol 20:157–198PubMedCrossRefGoogle Scholar
  32. 32.
    Ferjoux G, Bousquet C, Cordelier P, Benali N, Lopez F, Rochaix P, Buscail L, Susini C (2000) Signal transduction of somatostatin receptors negatively controlling cell proliferation. J Physiol Paris 94:205–210PubMedCrossRefGoogle Scholar
  33. 33.
    Hofland LJ, van Koetsveld PM, Wouters N, Waaijers M, Reubi JC, Lamberts SW (1992) Dissociation of antiproliferative and antihormonal effects of the somatostatin analog octreotide on 7315b pituitary tumor cells. Endocrinology 131:571–577PubMedCrossRefGoogle Scholar
  34. 34.
    Schally AV (1988) Oncological applications of somatostatin analogues. Cancer Res 48:6977–6985PubMedGoogle Scholar
  35. 35.
    Notas G, Kolios G, Mastrodimou N, Kampa M, Vasilaki A, Xidakis C, Castanas E, Thermos K, Kouroumalis E (2004) Cortistatin production by HepG2 human hepatocellular carcinoma cell line and distribution of somatostatin receptors. J Hepatol 40:792–798PubMedCrossRefGoogle Scholar
  36. 36.
    Lamberts SW, Reubi JC, Krenning EP (1994) The role of somatostatin analogs in the control of tumor growth. Semin Oncol 21:61–64PubMedGoogle Scholar
  37. 37.
    Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ (1996) Octreotide. N Engl J Med 334:246–54PubMedCrossRefGoogle Scholar
  38. 38.
    Lamberts SW, de Herder WW, Hofland LJ (2002) Somatostatin analogs in the diagnosis and treatment of cancer. Trends Endocrinol Metab 13:451–457PubMedCrossRefGoogle Scholar
  39. 39.
    Bousquet C, Guillermet J, Vernejoul F, Lahlou H, Buscail L, Susini C (2004) Somatostatin receptors and regulation of cell proliferation. Dig Liver Dis 36(Suppl 1):S2–S7PubMedCrossRefGoogle Scholar
  40. 40.
    Dasgupta P (2004) Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther 102:61–85PubMedCrossRefGoogle Scholar
  41. 41.
    Huynh H, Chow P, Ooi L, Soo K (2002) A possible role for Insulin-like Growth Factor-Binding Protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation. Cell Growth Differ 13:115–122PubMedGoogle Scholar
  42. 42.
    Adams RL, Adams IP, Lindow SW, Zhong W, Atkin SL (2005) Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. Br J Cancer 92:1493–1498PubMedCrossRefGoogle Scholar
  43. 43.
    Liu HL, Huo L, Wang L (2004) Octreotide inhibits proliferation and induces apoptosis of hepatocellular carcinoma cells. Acta Pharmacol Sin 25:1380–1386PubMedGoogle Scholar
  44. 44.
    Lasfer M, Vadrot N, Schally AV, Nagy A, Halmos G, Pessayre D, Feldmann G, Reyl-Desmars FJ (2005) Potent induction of apoptosis in human hepatoma cell lines by targeted cytotoxic somatostatin analogue AN-238. J Hepatol 42:230–237PubMedCrossRefGoogle Scholar
  45. 45.
    Xidakis C, Kolios G, Valatas V, Notas G, Mouzas I, Kouroumalis E (2004) Effect of octreotide on apoptosis-related proteins in rat Kupffer cells: a possible anti-tumour mechanism. Anticancer Res 24:833–841PubMedGoogle Scholar
  46. 46.
    Reynaert H, Rombouts K, Vandermonde A, Urbain D, Kumar U, Bioulac-Sage P, Pinzani M, Rosenbaum J, Geerts A (2004) Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma. Gut 53:1180–1198PubMedCrossRefGoogle Scholar
  47. 47.
    Notas G, Xidakis C, Valatas V, Vasilaki A, Mastrodimou N, Manousou P, Kolios G, Thermos K, Kouroumalis EA (2005) LPS modifies the expression and accumulation of Somatostatin receptors in rat Kupffer cells. J Hepatol 42(Suppl 2):232Google Scholar
  48. 48.
    Olias G, Viollet C, Kusserow H, Epelbaum J, Meyerhof W (2004) Regulation and function of somatostatin receptors. J Neurochem 89:1057–1091PubMedCrossRefGoogle Scholar
  49. 49.
    Hofland LJ, Lamberts SW (2003) The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 24:28–47PubMedCrossRefGoogle Scholar
  50. 50.
    Corbetta S, Ballare EMG, Lania A, Losa M, Di Blasio A, Spada AM (2001) Somatostatin receptor subtype 2 and 5 in human GH-secreting pituitary adenomas: analysis of gene sequence and mRNA expression. Eur J Clin Invest 31:208–214PubMedCrossRefGoogle Scholar
  51. 51.
    Valatas V, Kolios G, Manousou P, Notas G, Xidakis C, Diamantis I, Kouroumalis E (2004) Octreotide regulates CC but not CXC LPS-induced chemokine secretion in rat Kupffer cells. Br J Pharmacol 141:477–487PubMedCrossRefGoogle Scholar
  52. 52.
    Valatas V, Kolios G, Manousou P, Xidakis C, Notas G, Ljumovic D, Kouroumalis EA (2004) Secretion of inflammatory mediators by isolated rat Kupffer cells: the effect of octreotide. Regul Pept 120:215–225PubMedCrossRefGoogle Scholar
  53. 53.
    Slijkhuis WA, Stadheim L, Hassoun ZM, Nzeako UC, Kremers WK, Talwalkar JA, Gores GJ (2005) Octreotide therapy for advanced hepatocellular carcinoma. J Clin Gastroenterol 39:333–338PubMedCrossRefGoogle Scholar
  54. 54.
    Notas G, Kampa M, Nifli AP, Xidakis K, Papasava D, Thermos K, Kouroumalis E, Castanas E (2007) The inhibitory effect of opioids on HepG2 cells is mediated via interaction with somatostatin receptors. Eur J Pharmacol 555:1–7PubMedCrossRefGoogle Scholar
  55. 55.
    Kouroumalis E, Samonakis D, Skordilis P (2003) Octreotide treatment of hepatocellular carcinoma. Hepatology 37:477PubMedCrossRefGoogle Scholar
  56. 56.
    Deming D, Stella A, Holen K (2005) A dramatic response to long-acting octreotide in metastatic hepatocellular carcinoma. Clin Adv Hematol Oncol 3:468–474PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Dimitrios N. Samonakis
    • 1
    • 2
  • George Notas
    • 1
    • 2
  • Nikolaos Christodoulakis
    • 1
    • 2
  • Elias A. Kouroumalis
    • 1
    • 2
  1. 1.Department of Gastroenterology & HepatologyUniversity Hospital of HeraklionHeraklion, CreteGreece
  2. 2.Liver Research Laboratory, School of MedicineUniversity of CreteHeraklion, CreteGreece

Personalised recommendations